Catalog No.: PC-49671Not For Human Use, Lab Use Only.
SGL5213 (SGL 5213) is potent, intestinal sodium-dependent glucose cotransporter (SGLT) inhibitor with IC50 of 29 and 20 nM for hSGLT1 and hSDGLT2, respectively.
SGL5213 (SGL 5213) is potent, intestinal sodium-dependent glucose cotransporter (SGLT) inhibitor with IC50 of 29 and 20 nM for hSGLT1 and hSDGLT2, respectively.
SGL5213 had a glucose-lowering effect at 0.3 mg/kg (p.o.) in SD rats.
Orally administered SGL5213 was hardly absorbed and its distribution was restricted to the gastrointestinal lumen.
SGL5213 significantly improved post-prandial hyperglycemia in streptozotocin (STZ)-induced diabetic rats at doses of 1 mg/kg or more.
SGL5213 suppressed intestinal glucose absorption and enhances plasma GLP-1 and GLP-2 secretion in rats.
